You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

138 Results
Guidelines and Advice
Status: Current
ID: 3-14
Version: 3
Updated
Jun 2025
Guidelines and Advice
Updated
Jun 2025
Drug
Other Name(s): Arimidex®
Jun 2025
Drug
Other Name(s): Rituxan® , Truxima™ , Riximyo™ , Ruxience™ , Riabni™
Jun 2025
Drug
Jun 2025
Drug
Other Name(s): Adcetris®
Jun 2025
Drug
Other Name(s): Tafinlar®
Jun 2025
Drug
Other Name(s): Mekinist®
Jun 2025
Drug
Other Name(s): Rydapt®
Jun 2025
Regimen
Intent: Palliative, Curative
Funding:
New Drug Funding Program
    Aldesleukin (interleukin-2) - In-Transit Metastases from Melanoma
May 2019
Regimen
Cancer Type:
Sarcoma, 
Soft Tissue, 
Skin, 
Melanoma
Intent: Palliative
Jun 2025
Regimen
Cancer Type:
Gynecologic, 
Gestational Trophoblastic Disease
Intent: Curative
May 2019

Pages